H uman papillomavirus (HPV) infection is the most common sexually transmitted infection in the United States, with nearly 14 million new infections occurring every year. 1 Greater than 90% of cases of anogenital warts are associated with two specific types of HPV, 6 and 11. 2 Before introduction of the HPV vaccines in the United States, the prevalence of anogenital warts was estimated to be 5.6% among sexually active people 18 to 59 years old. 3 Females and males 20 to 24 years of age experienced the greatest burden of anogenital warts, with incidence rates as high as 6.3 and 2.9 per 1000 person-years, respectively. 4 Anogenital warts pose a significant challenge to both an individual's health and the healthcare system. Diagnoses of anogenital warts are associated with negative psychosocial outcomes, including anxiety and depression. 5 While clearance may occur spontaneously or with treatment, recurrences are common, occurring in approximately 30% of cases. 6 Treatment can be lengthy, lasting months and requiring multiple healthcare visits. The national estimated direct cost associated with anogenital warts is over $220 million per year. 7 HPV vaccination presents an opportunity to prevent nearly all cases of anogenital warts. Protection against HPV types 6 and 11 is provided by both the four-valent form of the HPV vaccine that has been available in the US since 2006 and the nine-valent vaccine that is in current use. Both vaccines were found to be highly efficacious against HPV types 6 and 11. 8, 9 Recommendations for routine administration to females at ages 11-12 years have been in place since 2006 in the United States, and similar recommendations for boys were introduced in 2011. Catch-up vaccination is recommended up to age 26 years for females and up to age 21 years for males; select high-risk males should be immunized to age 26 years. 6 As a recommended preventive health service, cost of the vaccine is covered by all major private insurance companies in the US and the federal Vaccines for Children program for low-income families. 10 The United States has achieved moderate levels of HPV vaccine coverage. As of 2016, 66% of adolescents between 13 and 17 years old had received at least 1 dose of the vaccine series and 49% completed the 2 or 3 dose series (depending on age at initiation). 11 Because the United States does not have a national system in place for providing immunizations, practice-based immunization is the predominant mode of delivery. Missed opportunities for vaccination can occur in this setting for a number of reasons, including missed health care visits, lack of clinician recommendations, and low parental acceptance due to negative or ambivalent attitudes and lack of knowledge. 12 While the efficacy of the vaccine has been established in numerous randomized trials, to determine its real-world benefit, it is important to assess both the population-level impact and post-licensure effectiveness of the vaccine outside of the tightly controlled settings of clinical trials. A recent systematic review and meta-analysis of HPV vaccine studies from around the world through 2016 reported high HPV vaccine impact on reducing anogenital warts. Significantly reduced risks of anogenital warts were observed for women 15 to 29 years old and men 15 to 24 years old when comparing the pre-and post-vaccination periods. The same review also reported that greater reductions in risk of anogenital warts were observed in countries with high coverage compared to countries with moderate coverage in both women and men. 13 The purpose of this systematic literature review is to provide the first detailed review of the studies in the United States that assess the real-world impact and effectiveness of the HPV vaccine as it relates to anogenital warts including studies through 2018. In the US, where coverage of the vaccine is moderate, assessing the population-level trends and post-licensure individual-level effectiveness of the vaccine is crucial to identifying areas where the prevention potential of the vaccines is not being fully realized.
MATERIALS AND METHODS
The PubMed, Medline, and Embase databases were searched for relevant articles published during January 1, 2006 to March 12, 2018, using prespecified search terms. Search terms included the following subheadings: "papillomavirus vaccination," "condylomata acuminata," "incidence," "prevalence," "program evaluation," "population surveillance," and "epidemiological monitoring" (See Supplemental Content for complete search terms, http://links.lww.com/OLQ/A323). Duplicate references were then removed. The following exclusion criteria were then applied to the titles and abstracts of identified articles: studies not written in English, studies focused solely on the bivalent vaccine, review or editorial articles, modeling studies, cost-effectiveness analyses, clinical trials, studies set outside the United States, studies that did not measure the desired outcome of anogenital warts after introduction of vaccine, and conference abstracts with no associated papers. The full texts of the remaining articles were then assessed for eligibility using the same exclusion criteria. A Web of Science cited reference search was then performed using the eligible full-text articles to determine if any eligible articles were missed.
All eligible articles were then classified as either impact or effectiveness studies. Impact studies are those that are ecological in nature and describe population-based trends in the diagnoses of anogenital warts before and after introduction of HPV vaccines.
Effectiveness studies are those that include individual-level vaccination histories and compared reductions in risks of warts between vaccinated and unvaccinated individuals in the post-licensure setting of use in real world conditions. Using quality assessment tables, all eligible articles were deemed of sufficient scientific rigor to include (see Supplemental Content for details, http:// links.lww.com/OLQ/A324).
A standardized table was then used to extract the following information from each eligible full-text article: study location, data source, study population, sample size, data collection dates, and study design. Estimates of trends in anogenital warts or vaccine effectiveness against anogenital warts were then described for each included study, including results by available covariates, such as age and sex. This systematic review was registered with PROSPERO (registration number: 42018091189), an international database of prospectively registered systematic reviews with health-related outcomes. This review was found to be exempt from review by the Yale University Institutional Review Board.
RESULTS

Search Results
A total of 2,301 articles were initially identified. Of these, 892 were duplicates, leaving 1,409 unique references. After applying exclusion criteria to all titles, abstracts, and full text articles, 8 studies were determined to be eligible based on our inclusion criteria ( Fig. 1) . No other studies were identified in the Web of Science cited reference search. Of these eight studies, five were then classified as impact studies and three as effectiveness studies, and they are summarized below. 
Impact Studies
A total of five impact studies were identified ( Table 1 ). The first report of trends in anogenital warts in the post-vaccine era by Bauer et al. was conducted in California among low-income individuals receiving family planning services and estimated vaccine impact by subtracting the rate of anogenital warts in the last year of observation to the rate in the first year (2010 and 2007, respectively). In this study, the largest declines in anogenital warts (34.8%) were observed among women younger than 21 years. Significant decreases were also observed among women and men ages 25 years and younger though no declines were seen in either men or women older than 25 years.
14 In the first study using a national sample, Flagg et al. assessed the impact of HPV vaccines by estimating the annual trends of anogenital wart prevalence. Unlike the previous study from Bauer et al., this study also included data from the pre-vaccine periods (2003 to 2010), which allowed it to account for pre-existing trends. In this study, decreases in the prevalence of anogenital warts were seen in women aged 15 16 A follow-up study was done by Flagg et al. that extended their previous national sample to include data up through 2014. In contrast to the first study where little or no impact was seen among men, this follow-up study demonstrated a clear and statistically significant trend reversal of a decline post-2011 among males aged 15 to 24 years. 17 Nsouli-Maktabi et al. examined diagnoses in active duty armed services members and only observed declines in the annual rates of anogenital warts in females less than 25 years of age and no significant rate changes were seen among males of all ages and females aged 25 years and older. 18 Visual display of results is presented in Figure 2 .
Effectiveness Studies
A total of three effectiveness studies were identified (Table 2) . Two studies focused on effectiveness of the vaccine to prevent anogenital warts in females and estimated how the number and the timing of doses affected the risk of anogenital warts. Overall, they found that having 3 doses (the full series recommended at that time) provided the greatest protection. Both studies also reported effectiveness with fewer doses, though to a lesser degree than three. Hariri et al. studied female enrollees in an integrated healthcare delivery system in three areas in the United States. The study utilized a 6-month buffer period from last vaccine dose to account for possible undiagnosed anogenital warts before vaccination. They found that risk of anogenital warts decreased by 68% for 2 doses separated by greater than 6 months and 77% for 3 doses compared to those unvaccinated. 19 Perkins et al. evaluated girls aged 9 to 18 years enrolled in commercial providersponsored insurance plans also found that the incidence rate of anogenital warts was 30.8% lower among those who received 3 doses (1.5 cases/1000 person-years) compared to those who received zero doses (2.17 cases/1000 person-years). 20 The third study focused on the effectiveness of the vaccine in men who have sex with men aged 26 years and older through a post-hoc analysis of a cohort study. It found that risk for anogenital warts decreased by 55% with 3 doses of vaccine. This estimate was adjusted for potential confounders, including history of anogenital warts. 21 
DISCUSSION
More than 12 years have passed since HPV vaccination was implemented in the US. At this point in time, reviewing the evidence for impact and post-licensure effectiveness of HPV vaccines is crucial to determine if progress is being made at preventing HPV-associated diseases in real-world settings. Given that the majority of anogenital warts appear between 2-3 months from incident infection, this outcome may serve as one of the first clinical indicators of the real-world effect of the vaccine. 22 Once determined, the impact and effectiveness may highlight potential areas of needed improvement in vaccination efforts to achieve the desired reductions in HPV infections and associated sequelae.
Post-vaccine introduction, the most consistent finding among all studies was a reduced rate of anogenital warts among females 25 years of age and younger. Two of the studies (Perkins et al., Flagg et al.) reported that the incidence rate of anogenital warts was actually rising during the pre-vaccine era. 15, 16 Evaluating vaccine impact with data gathered only during the post-vaccine period may not account for the previous secular trends and thus could over-or under-estimate impact attributed to the vaccine. Assuming there were no systemic or extraneous influences on anogenital warts diagnoses during those study periods, a reversal from an upward to a downward trend post-vaccine introduction provides compelling evidence that HPV vaccines have reversed this trend and are contributing to the reduction of anogenital warts among younger females.
In contrast to the strong evidence of vaccine impact in females ages 25 years or younger, data to support real-world impact among men and women older than 25 years are limited. The little or no population-level impact seen in these groups are likely due to either their lower likelihood of vaccination or to vaccination after natural exposure given their age when the vaccine was introduced. Because the vaccine is prophylactic and not therapeutic, limited declines might be expected in these age groups during this review period. For males ages 25 and younger, declines in diagnoses of anogenital warts did occur, but the timing of these declines varied. Observed declines prior to routine male vaccination in 2011 could reflect some degree of herd immunity provided by vaccination of females. Studies that showed declines after male vaccination was routinely recommended likely reflect the direct effect of male vaccination. With a shorter period of time available to asses the direct impact on males, future monitoring of these trends is important.
Direct assessment in studies that compared vaccinated to unvaccinated populations is critical in the post-licensure period to determine real-world vaccine effectiveness as it is being used in clinical practice. These studies also demonstrate the benefit of the vaccine on reducing risk of anogenital warts at the individual level. These studies reported a reduced risk of anogenital warts for individuals who received at least one dose of the vaccine compared to those who were unvaccinated. This reduction in risk was seen in both females and men who have sex with men and demonstrated a dose-response effect (increased effectiveness with increasing number of doses of the vaccine received). More research is needed to assess if the effectiveness of the vaccine will vary significantly with the most recent 2-dose schedule. Countries with moderate HPV vaccination coverage similar to the US have achieved comparable declines in anogenital warts. For example, in Germany, one year after vaccine introduction, there was a 23% reduction in incidence of anogenital warts among females aged 15 to 19 years. 23 Similar to data from the US, evidence of vaccine impact among males in other countries have been mixed. For example, a study in Ontario, Canada did not observe decreases in males of any age after beginning female vaccination while another study set in Quebec during the same time period found decreases of 21% in males aged 15 to 19 years. 24, 25 These findings suggest that in countries with moderate vaccine uptake like the US, herd immunity may only play a low to modest role in preventing disease. Estimates of vaccine effectiveness in the US were also comparable to that observed in other counties; a provincial cohort study in Canada found a 56% vaccine effectiveness against anogenital warts among those who received three doses before the age of 18. 26 Similarly, an effectiveness study set in Sweden found a 76% vaccine effectiveness for those who received three doses before the age of 20.
27
In countries with national immunization delivery systems and high HPV vaccine uptake, reductions in anogenital warts have been greater than those observed in the United States. In an analysis of the national patient registry for Denmark, a statistically significant decline of 45.3% was observed in females aged 16-17 years old after introduction of the four-valent vaccine. 28 In Australia, the diagnoses of anogenital warts were nearly eliminated in women younger than 21 years old, decreasing by 92.6% from 2007 to 2011. 29 In addition to the overall greater reductions in anogenital warts in women residing in high vaccine coverage countries, these countries may also experience a greater herd immunity effect. A study in Australia found an 81.8% decrease in diagnoses of anogenital warts in males younger than 21 years old. 29 These findings demonstrate the substantial prevention potential of HPV vaccines for the US if higher coverage could be achieved.
Our review did have some limitations. Because of the small number of eligible studies, our review was descriptive and narrative, and no formal meta-analysis was conducted. However, the included studies did cover a wide range of populations, including national samples, men who have sex with men, and adolescents. Furthermore, as with any systematic literature review, there exists the possibility of publication bias. However, included studies did have both positive and negative results, reflecting a range of findings.
Even with suboptimal uptake of the vaccine, the United States has experienced significant declines in the rates of anogenital warts. However, the magnitude of declines and effects for some populations (e.g., men) have been modest compared to countries with higher uptake, suggesting that the full prevention potential of these vaccines has not yet been reached in the United States. Ongoing monitoring is needed to continue to assess progress, and greater efforts to increase immunization are needed to further reduce the incidence of anogenital warts and their associated individual and public health consequences in the US. 
